TCRT: רווח נקי למניה (EPS TTM) Alaunos Therapeutics Inc.

Alaunos Therapeutics (TCRT) is developing TCR-T methods to combat solid tumors through non-viral immune modification. The company is pursuing expansion within the GI oncology segment by scaling its technological developments. The business is currently undergoing a rigorous restructuring to preserve capital and sell patents. The EPS trend over the last 12 months reflects profitability dynamics, with the latest figure standing at -1.94.

The development of TCR-T cell therapy for the treatment of solid tumors determines the future capitalization of Alaunos Therapeutics (TCRT). Net income per share TTM reflects the portion of profit attributable to a single security over the year. This metric allows for an assessment of the actual efficiency of capital management. An analysis of the net income per share TTM trend reveals the pace of the transition to monetization via insurance reimbursements. This indicator serves as the basis for the long-term valuation of the asset's fundamental value.